21:48 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

AzurRx reports Phase IIa data for MS1819 in chronic pancreatitis

In September, AzurRx BioPharma Inc. (NASDAQ:AZRX) reported data from 6 patients with chronic pancreatitis in a Phase IIa trial showing that once-daily MS1819 for 48-60 days led to a >21% improvement in coefficient of fat...
05:04 , Jun 16, 2017 |  BC Week In Review  |  Financial News

AzurRx completes $5M private placement

GI disease company AzurRx BioPharma Inc. (NASDAQ:AZRX) raised $5 million through the sale of 1.4 million units at $3.50 in a private placement on June 8. Each unit comprises a share; a series A warrant...
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
22:02 , Nov 28, 2016 |  BC Week In Review  |  Clinical News

MS1819: Ph IIa started

AzurRx began an open-label, dose-escalation, Australian and New Zealand Phase IIa trial to evaluate 280, 560, 1,120 and 2,240 mg doses of MS1819 daily for 48-60 days in about 12 patients. Under an amended 2010...
20:26 , Nov 23, 2016 |  BC Week In Review  |  Clinical News

MS1819: Ph IIa started

AzurRx began an open-label, dose-escalation, Australian and New Zealand Phase IIa trial to evaluate 280, 560, 1,120 and 2,240 mg doses of MS1819 daily for 48-60 days in about 12 patients. Under an amended 2010...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Financial News

AzurRx completes IPO

AzurRx BioPharma Inc. (NASDAQ:AZRX), New York, N.Y.   Business: Gastrointestinal   Date completed: 2016-10-11   Type: IPO   Raised: $5.3 million   Shares: 960,000   Price: $5.50   Shares after offering: 9.6 million   Underwriters:...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Financial News

AzurRx amends IPO

AzurRx BioPharma Inc. , New York, N.Y.   Business: Gastrointestinal   Date announced: 2016-10-05   Type: IPO   To be raised: Up to $6.6 million   Shares: 1.2 million   Price: $5.50   Underwriters: WallachBeth...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Reasonable rally

Steve Edelson, Senior Editor   It looks like biotech's rebound will continue through the end of the year, but not with enough gusto to match the third quarter, or to make up for losses in...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Financial News

AzurRx amends IPO

AzurRx BioPharma Inc. , New York, N.Y.   Business: Gastrointestinal   Date announced: 2016-09-02   Type: IPO   To be raised: Up to $13.6 million   Shares: 1.7 million   Price: $6-$8   Underwriters: WallachBeth...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Financial News

AzurRx amends IPO

AzurRx BioPharma Inc. , New York, N.Y.   Business: Gastrointestinal   Date announced: 2016-07-29   Type: IPO   To be raised: Up to $15 million   Shares: 2.1 million   Price: $6-$8   Underwriters: WallachBeth...